● pepmg Research Desk · Peer-reviewed evidence review
What the research says about livagen
A neutral summary of the peer-reviewed literature on Livagen, a synthetic Lys-Glu-Asp-Ala tetrapeptide bioregulator studied almost entirely by a single research lineage in human-cell-culture, in-vitro, and animal models, with no controlled human clinical trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Livagen is described in the literature as a synthetic tetrapeptide, Lys-Glu-Asp-Ala ("KEDA"), one of the Khavinson-type short peptide bioregulators, studied almost entirely by a single research lineage in human-cell-culture, in-vitro, and animal models [1][9].
- Most of the human-tissue work is in vitro: in cultured lymphocytes from elderly donors, investigators reported that Livagen decondensed ("reactivated") heterochromatin and activated ribosomal genes [1][2][3][4].
- Additional in-vitro and animal work reports that Livagen inhibited enkephalin-degrading enzymes in human serum and altered digestive-enzyme and protein-synthesis activity in rat tissues [7][8][10].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What livagen is
Livagen is described in the literature as a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), obtained by directed chemical synthesis based on amino-acid analysis of liver peptide preparations and grouped with the Khavinson short peptide bioregulators (also called "cytogens") studied largely by one research lineage [1][10]. In the authors' own framing, Livagen is characterized as a chromatin-modifying, geroprotective peptide [6].
Livagen is not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only and is not a regulated pharmaceutical.
What the research has measured
Preclinical onlyThe interventional evidence for livagen is entirely preclinical, human-cell-culture, in-vitro, and animal. The most-cited human-tissue work is in vitro: in cultured lymphocytes from elderly donors (reported across studies as 75 to 88 and 80 to 91 years old), investigators reported that Livagen activated ribosomal genes and induced decondensation ("deheterochromatinization") of pericentromeric structural heterochromatin and of facultative heterochromatin [1][2][3][4][5]. These are structural chromatin changes measured in donor cells in culture, not measurements of any clinical outcome in people.
Combined-treatment studies paired Livagen with cobalt ions and reported that it modified chromosomal changes in cultured lymphocytes from elderly donors and from patients with atherosclerosis [3][6]. In another in-vitro human system, Livagen was reported to inhibit enkephalin-degrading enzymes in human serum [7].
Animal work reports tissue-level effects. Oral Livagen was reported to change digestive-enzyme activity in the gastrointestinal tract of rats, with reductions in young animals and increases in old animals; in vitro it reduced a small-intestinal dipeptidase activity by 50% [8]. In organotypic and monolayer cultures, Livagen was reported to stimulate the growth of liver-derived explants and to increase protein synthesis in hepatocytes from rats of different ages, with the largest effect in cells from old animals [9][10].
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of administered livagen from which to report human adverse-event rates. The human-tissue data are in-vitro studies on donor cells and serum, and the interventional data are in animals and cell cultures [1][7][8].
Because these are single-group preclinical and in-vitro studies, they generally report the peptide's measured activities rather than adverse events, and none of the cited abstracts characterize a human safety profile. One rat study described Livagen as a weakly hydrolyzed peptide and reported age-dependent changes in digestive-enzyme activity without reporting adverse effects [8]; this is a measured research observation in animals, not a human safety characterization.
Because the human data are in-vitro and the interventional data are preclinical, nothing here should be read as a safety guarantee for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for livagen is characterized as preclinical: it consists of in-vitro studies on human lymphocytes and serum from elderly donors, plus animal tissue and cell-culture work, produced almost entirely by a single research lineage, with no controlled human clinical trials [1][3][8]. "Preclinical" describes the design and scope of the published studies, chromatin decondensation in cultured donor lymphocytes, enzyme-activity changes in rat tissue, and protein-synthesis changes in cultured hepatocytes, not an endorsement and not an anti-aging benefit demonstrated in people [1][8][10].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 10
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people.
- Effects of short peptides on lymphocyte chromatin in senile subjects.
- Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.
- Anti-aging peptide bioregulators induce reactivation of chromatin.
- EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
- [Genomic instability in atherosclerosis].
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].
- Tissue-specific effects of peptides.
- [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.